0B68 Hann, Hie-Won L - Thomas Jefferson University - Thomas Jefferson University
hlh102

Hie-Won L. Hann, MD

Contact Dr. Hann

32 South 10th Street
Main Building, Suite 480
Philadelphia, PA 19107

(215) 955-8900
(215) 503-2527 fax

Most Recent Peer-reviewed Publications

  1. Then and now: The progress in hepatitis B treatment over the past 20 years
  2. Randomized comparison of Tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B
  3. Correlates of Hepatitis B Virus Health-Related Behaviors of Korean Americans: A Situation-Specific Nursing Theory
  4. Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients
  5. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection - Results from a clinic-based longitudinal cohort
  6. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: A nested case-control analysis
  7. Erratum: Recognition and management of HBV infection in a social context (Journal of Cancer Education DOI: 10.1007/s13187-011-0203-5)
  8. Relative telomere length: A novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection
  9. The management of chronic hepatitis B in Asian Americans
  10. Recognition and management of HBV infection in a social context
  11. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
  12. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated.
  13. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated
  14. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment
  15. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009)
  16. Telbivudine: An effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses
  17. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
  18. Response
  19. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B
  20. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)
0